Noguerado-Mellado Blanca, Gamboa Abdonias R, Perez-Ezquerra Patricia R, Cabeza Cristina M, Fernandez Roberto P, De Barrio Fernandez Manuel
Hospital General Universitario Gregorio Marañón. Allergy Department, 46 th Doctor Esquerdo Avenue, 28007 Madrid, Spain.
Recent Pat Inflamm Allergy Drug Discov. 2016;10(1):61-63. doi: 10.2174/1872213x10999160404115504.
Naproxen is a non-steroidal anti-inflammatory drug (NSAID), belonging to propionic acid group, and its chemical structure is a 6-metoxi-metil-2-naftalenoacetic acid. Fixed drug eruptions (FDE) have been rarely reported.
A 38-year-old woman referred that after 2 hours of taking 2 tablets of naproxen for a headache, she developed several edematous and dusky-red macules, one on right forearm and the other two in both thighs and she was diagnosed with FDE probably due to naproxen.
We performed patch testing (PT) (Nonweven Patch Test Strips Curatest® Lohman & Rauscher International, Rangsdorf, Germany), with ibuprofen (5% Petrolatum), ketoprofen (2.5% Petrolatum), naproxen and nabumetone (both 10% in DMSO) on the residual lesion of the forearm with naproxen and in both thighs with ibuprofen, ketoprofen and nabumetone.
Readings at day 1 (D1) and day 2 (D2) showed negative results to ibuprofen, ketoprofen and nabumetone, but were positive to naproxen in D1. A single blind oral challenge test (SBOCT) with other propionic acid derivates were performed in order to check for crossreactivity between them: ibuprofen, ketoprofen and nabumetone were administered and all drugs were well tolerated.
In our patient PT confirmed the diagnosis and allowed us to study the cross-reactivity between NSAIDs of the same group, and confirmed by SBOCT. Cross-reactivity between propionic acid derivatives was studied. This is a case of hypersensitivity to naproxen with good tolerance to other propionic acids NSAIDs (ibuprofen and ketoprofen) and nabumetone, confirmed by PT and SBOCT. Some relavent patents for fixed drug eruption are discussed.
萘普生是一种非甾体抗炎药(NSAID),属于丙酸类,其化学结构为6-甲氧基-甲基-2-萘乙酸。固定性药疹(FDE)鲜有报道。
一名38岁女性称,因头痛服用2片萘普生2小时后,她出现了几处水肿性暗红色斑疹,一处在右前臂,另外两处分别在双侧大腿,她被诊断为可能由萘普生引起的固定性药疹。
我们在前臂有萘普生残留皮损处以及双侧大腿使用布洛芬(5%凡士林)、酮洛芬(2.5%凡士林)、萘普生和萘丁美酮(均为10%二甲基亚砜溶液)进行斑贴试验(PT)(使用德国朗斯多夫的洛曼&劳舍尔国际公司生产的Nonweven Patch Test Strips Curatest®)。
第1天(D1)和第2天(D2)的读数显示,布洛芬、酮洛芬和萘丁美酮的结果为阴性,但D1时萘普生的结果为阳性。为检查它们之间的交叉反应性,对其他丙酸衍生物进行了单盲口服激发试验(SBOCT):给予布洛芬、酮洛芬和萘丁美酮,所有药物耐受性良好。
在我们的患者中,斑贴试验证实了诊断,并使我们能够研究同一组非甾体抗炎药之间的交叉反应性,单盲口服激发试验也予以了证实。研究了丙酸衍生物之间的交叉反应性。这是一例对萘普生过敏但对其他丙酸类非甾体抗炎药(布洛芬和酮洛芬)以及萘丁美酮耐受性良好的病例,斑贴试验和单盲口服激发试验均予以了证实。讨论了一些与固定性药疹相关的专利。